Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, announced the completion of its Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction.

Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its positive results of the interim analysis of Recardio's Phase II clinical trial in AMI were published in the latest release of the European Heart Journal. The current version of the journal relates to the presentation during the 2020 Congress of the European Society of Cardiology.

50% Commission Offering for Initial Distributors. Amnio-Maxx™ will be used to treat various conditions in orthopedics and sports medicine.

Dr. Sugar and his team of medical professionals are set to offer state-of-the-art regenerative medicine to Sarasota and patients in the surrounding area. Regenerative medicine offers a powerful alternative to surgery, using the body's natural ability to heal itself and implementing it into treating injuries ranging from tennis elbow to arthritis. In pursuit of offering regenerative medicine, Dr. Sugar has teamed up with two of the most respected and experienced organizations available.